Company Filing History:
Years Active: 2013
Title: The Innovative Contributions of Patrick Woda in the Field of Pharmaceutical Sciences
Introduction
Patrick Woda is an accomplished inventor based in Vienna, Austria, recognized for his contributions to the field of pharmaceutical sciences. With one notable patent to his name, Woda is making strides in the development of innovative treatments for various diseases. His work demonstrates an impressive commitment to addressing complex health challenges through scientific innovation.
Latest Patents
Woda's most significant patent involves compounds that inhibit semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1). This patent, described as focusing on a general formula with an oxime moiety or a pharmaceutically acceptable salt, hydrate, or solvate thereof, outlines its use in preventing and treating SSAO/VAP-1 related diseases. These diseases encompass a variety of health concerns, including acute or chronic inflammatory diseases, diabetic complications, and neurodegenerative conditions. The potential applications of Woda's invention could significantly impact the treatment landscape for patients suffering from these diseases.
Career Highlights
Currently, Patrick Woda is employed at Semmelweis University, where he continues to develop and refine his innovative approaches to healthcare. His academic background and research focus contribute to creating lasting solutions in pharmaceutical sciences. Woda's unique insights and research efforts emphasize the importance of continuous innovation in health-related fields.
Collaborations
Throughout his career, Woda has collaborated with esteemed colleagues, notably Péter Mátyus and Kálmán Magyar. These partnerships enhance the breadth of his research, allowing for shared knowledge and resources that drive innovation and facilitate new discoveries in the pharmaceutical industry.
Conclusion
Patrick Woda stands out as a significant contributor to pharmaceutical innovations. His patent concerning compounds for inhibiting SSAO/VAP-1 showcases his dedication to advancing medical science and improving patient outcomes. As he continues to collaborate with esteemed professionals and work at Semmelweis University, the future of his inventions holds great promise for transforming the treatment of various diseases.